Q3 earnings beat estimates, but shares dip as 2025 sales outlook narrows. Get key highlights and pharma market insights.

Merck boosts its full-year outlook as third-quarter earnings top estimates following strong demand for its blockbuster cancer ...

Merck's Q3 2025 results saw huge growth in Winrevair and Capvaxive sales. Check out why I maintain my Strong Buy rating on ...

Thinking about picking up some Merck KGaA shares, but wondering if the current price tag does the business justice? You're not alone. Value hunters and long-term investors keep asking the same ...

Global pharmaceutical company Merck (NYSE:MRK) will be reporting earnings this Thursday morning. Here’s what you need to know ...

Merck shares dipped after strong earnings and higher profit guidance, as the company narrowed its 2025 sales forecast amid ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

Investing.com - Merck&Co (NYSE: MRK) reported third quarter EPS of $2.58, $0.23 better than the analyst estimate of $2.35. Revenue for the quarter came in at $17.28B versus the consensus estimate of ...

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

Merck MRK will report its third-quarter 2025 earnings on Oct. 30, before market open. The Zacks Consensus Estimate for ...

Pfizer currently has a 7% yield, and the company is making important business moves. Bristol Myers Squibb has a 5.6% yield ...